In 340,000 UK adults, low-to-moderate wine drinking was tied to lower heart-death risk while beer and spirits were tied to higher — but it’s observational, not proof.
At very high intravenous doses, vitamin C flips from antioxidant to pro-oxidant, generating a compound that preferentially damages stressed cancer cells. It’s still experimental.
Mapping brain tissue from donors aged 20 to 95, researchers saw the hippocampus’s immune cells transform in midlife — a possible link between aging and dementia.
Nagoya University researchers found it’s not the complement protein C3 in the blood that matters, but the C3 produced at the tumor — and it helps immunotherapy work.
The partnership pairs Evotec’s AI-driven discovery platforms with Odyssey’s disease biology to find small-molecule drugs for immune-driven conditions.
A new screening platform systematically finds drugs that tag disease proteins for disposal — including targets that conventional inhibitors can’t touch.
The digital musculoskeletal-care company is expanding into gut health — a huge, underserved market — with plans for one combined app in 2027.
A UConn project won a $500,000 grant to make low-cost DHA powder from microalgae grown on brewery waste, targeting a key nutrient gap for pregnant women.
Edinburgh and Bristol researchers traced disc degeneration to a collagen defect and mineral buildup — and found existing drugs could slow it, hinting at alternatives to surgery.
The deal adds gildeuretinol, a modified vitamin A in Phase 3 for Stargardt disease, to Tarsus — a program championed by Vertex founder Josh Boger.
Backed by Bezos and Gates funds, the company’s fungal-genome platform yielded LIFE-001, a long-acting drug that suppresses transplant rejection while sparing the brain.
The orexin-boosting pill treats the underlying biology of narcolepsy type 1 — keeping patients awake and curbing cataplexy — and opens a lucrative new drug class.